San Diego-centered Viking Therapeutics marked alone as a significant competitor from the weight loss drug industry in February after revealing promising details from a mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when offered being a weekly injection and in March the company unve